Treating mCRPC patients who have progressed on AR-directed therapy
Treating mCRPC patients who have progressed on AR-directed therapy
Dr Fabio Schutz
Dr. Fabio Schutz addresses a key challenge when treating patients with metastatic castration resistant prostate cancer (mCRPC). What do you do if they progress on an androgen receptor (AR) directed therapy?
Dr Fabio Schutz
Medical Oncologist
Beneficencia Portuguesa de São Paulo
Brazil
| 
5 min
|
Mar 2020
download resources
I agree that this educational programme:
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
17 min
Other programmes developed by Dr Fabio Schutz
Dr Fabio Schutz
Medical Oncologist
Beneficencia Portuguesa de São Paulo
Brazil
